Penumbra price to free cash flow PEN

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 59.2×
8-year median: 72.4×
Against its 8-year history: 11th; percentile: 0 is its lowest day, 100 its highest
8-year range: 54.9× to 495×
Peer median: 18.5×

Penumbra's price to free cash flow is 59.2× as of Oct 23, 2026.

That is below its 8-year median of 72.4×, lower than on 89% of days in the last 8 years.

Over that time it ranged from 54.9× in Oct 2025 to 495× in Dec 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 18.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	59.2×	57.9×	92.2×
2025	81.3×	54.9×	81.3×
2024	68.6×	59.7×	223×
2023	205×	148×	211×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	489×	457×	489×
2019	468×	233×	478×
2018	495×	495×	495×

Against its peers

Companies in Medical - Instruments & Supplies nearest Penumbra's size, closest first, today.

Company	Price to free cash flow
PENPenumbra	59.2×
COOCooper Companies	17.2×
SOLVSolventum	n/m
ALGNAlign Technology	17.3×
GMEDGlobus Medical	14.5×
PODDInsulet	35.2×
MSAMSA Safety	19.8×
WSTWest Pharmaceutical Services	63.2×
MMSIMerit Medical Systems	27.4×
HAEHaemonetics	18.5×
VNTVontier	12.1×
Peer median	18.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Penumbra

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.